Synergistic antitumor effect of suberoylanilide hydroxamic acid and cisplatin in osteosarcoma cells

about

Synergistic antitumor effect of suberoylanilide hydroxamic acid and cisplatin in osteosarcoma cells

Item

http://www.wikidata.org/entity/Q57922472

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована в жовтні 2018

@uk

name

Synergistic antitumor effect o ...... isplatin in osteosarcoma cells

@en

Synergistic antitumor effect o ...... isplatin in osteosarcoma cells

@nl

type

Item

label

Synergistic antitumor effect o ...... isplatin in osteosarcoma cells

@en

Synergistic antitumor effect o ...... isplatin in osteosarcoma cells

@nl

prefLabel

Synergistic antitumor effect o ...... isplatin in osteosarcoma cells

@en

Synergistic antitumor effect o ...... isplatin in osteosarcoma cells

@nl

P1476

Synergistic antitumor effect o ...... isplatin in osteosarcoma cells

@en

P2093

Guowei Zuo

http://www.w3.org/2001/XMLSchema#string

Hao Wang

http://www.w3.org/2001/XMLSchema#string

Mengyi Hou

http://www.w3.org/2001/XMLSchema#string

Shujuan Yan

http://www.w3.org/2001/XMLSchema#string

Sicheng Chen

http://www.w3.org/2001/XMLSchema#string

Tianyu Feng

http://www.w3.org/2001/XMLSchema#string

Yuxi Su

http://www.w3.org/2001/XMLSchema#string

Zhenglan Huang

http://www.w3.org/2001/XMLSchema#string

P2860

Epigenetic therapy of cancer with histone deacetylase inhibitors

Emerging roles of caspase-3 in apoptosis

Cisplatin: mode of cytotoxic action and molecular basis of resistance

A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.

Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.

Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.

Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma.

Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer.

Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer.

Preclinical studies of chemotherapy using histone deacetylase inhibitors in endometrial cancer

P304

4663-4670

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/OL.2018.9224

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30197679

http://www.w3.org/2001/XMLSchema#string

P921

cancer research

P932

6126343

http://www.w3.org/2001/XMLSchema#string